Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference

NEW YORK – March 13, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President…

BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”

Event:   BIO CEO & Investor Conference 2017 Date/Time:      Tuesday, February 14, 2017 from 2:30 p.m. to 3:25 p.m. Eastern Time Location:         The Waldorf Astoria Hotel in New York, NY https://www.bio.org/events/bio-ceo-investor-conference Christopher U. Missling, PhD, President and Chief Executive Officer will participate on the panel titled “Designing Clinical Trials in a 21st Century Cures…

Alzheimer’s Association International Conference 2016 (AAIC) – July 24, 2016

Event: Poster presentation: New Exploratory Alzheimer’s Drug ANAVEX 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients Date/Time: Sunday, July 24, 2016 9:30 a.m. to 10:30 a.m. EDT Location: Hall D/E, Metro Toronto Convention Centre, Toronto, ON